vs
Alkermes plc.（ALKS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Alkermes plc.的1.6倍（$622.0M vs $384.5M），Royalty Pharma plc净利率更高（34.4% vs 12.8%，领先21.6%），Royalty Pharma plc同比增速更快（4.8% vs -10.6%），过去两年Alkermes plc.的营收复合增速更高（4.8% vs 4.6%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ALKS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.6倍
$384.5M
营收增速更快
RPRX
高出15.3%
-10.6%
净利率更高
RPRX
高出21.6%
12.8%
两年增速更快
ALKS
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $622.0M |
| 净利润 | $49.3M | $214.2M |
| 毛利率 | 88.0% | — |
| 营业利润率 | 15.1% | 62.4% |
| 净利率 | 12.8% | 34.4% |
| 营收同比 | -10.6% | 4.8% |
| 净利润同比 | -66.3% | 2.9% |
| 每股收益（稀释后） | $0.29 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRPRX
| Q4 25 | $384.5M | $622.0M | ||
| Q3 25 | $394.2M | $609.3M | ||
| Q2 25 | $390.7M | $578.7M | ||
| Q1 25 | $306.5M | $568.2M | ||
| Q4 24 | $430.0M | $593.6M | ||
| Q3 24 | $378.1M | $564.7M | ||
| Q2 24 | $399.1M | $537.3M | ||
| Q1 24 | $350.4M | $568.0M |
净利润ALKSRPRX
| Q4 25 | $49.3M | $214.2M | ||
| Q3 25 | $82.8M | $288.2M | ||
| Q2 25 | $87.1M | $30.2M | ||
| Q1 25 | $22.5M | $238.3M | ||
| Q4 24 | $146.5M | $208.2M | ||
| Q3 24 | $92.4M | $544.0M | ||
| Q2 24 | $91.4M | $102.0M | ||
| Q1 24 | $36.8M | $4.8M |
毛利率ALKSRPRX
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
营业利润率ALKSRPRX
| Q4 25 | 15.1% | 62.4% | ||
| Q3 25 | 22.6% | 70.1% | ||
| Q2 25 | 23.8% | 36.3% | ||
| Q1 25 | 4.5% | 94.0% | ||
| Q4 24 | 37.8% | 60.9% | ||
| Q3 24 | 27.7% | — | ||
| Q2 24 | 27.5% | 50.2% | ||
| Q1 24 | 12.4% | -13.0% |
净利率ALKSRPRX
| Q4 25 | 12.8% | 34.4% | ||
| Q3 25 | 21.0% | 47.3% | ||
| Q2 25 | 22.3% | 5.2% | ||
| Q1 25 | 7.3% | 41.9% | ||
| Q4 24 | 34.1% | 35.1% | ||
| Q3 24 | 24.4% | 96.3% | ||
| Q2 24 | 22.9% | 19.0% | ||
| Q1 24 | 10.5% | 0.8% |
每股收益（稀释后）ALKSRPRX
| Q4 25 | $0.29 | $0.49 | ||
| Q3 25 | $0.49 | $0.67 | ||
| Q2 25 | $0.52 | $0.07 | ||
| Q1 25 | $0.13 | $0.55 | ||
| Q4 24 | $0.88 | $0.46 | ||
| Q3 24 | $0.55 | $1.21 | ||
| Q2 24 | $0.53 | $0.23 | ||
| Q1 24 | $0.21 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.8B | $9.7B |
| 总资产 | $2.5B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ALKSRPRX
| Q4 25 | $388.6M | $618.7M | ||
| Q3 25 | $616.4M | $938.9M | ||
| Q2 25 | $521.2M | $631.9M | ||
| Q1 25 | $399.8M | $1.1B | ||
| Q4 24 | $291.1M | $929.0M | ||
| Q3 24 | $396.3M | $950.1M | ||
| Q2 24 | $535.1M | $1.8B | ||
| Q1 24 | $420.8M | $843.0M |
总债务ALKSRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ALKSRPRX
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.7B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.3B | $9.8B | ||
| Q1 24 | $1.3B | $9.9B |
总资产ALKSRPRX
| Q4 25 | $2.5B | $19.6B | ||
| Q3 25 | $2.3B | $19.3B | ||
| Q2 25 | $2.3B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.1B | $18.2B | ||
| Q3 24 | $2.2B | $18.0B | ||
| Q2 24 | $2.2B | $17.7B | ||
| Q1 24 | $2.1B | $16.1B |
负债/权益比ALKSRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | — |
| 自由现金流率自由现金流/营收 | 44.2% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 3.45× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSRPRX
| Q4 25 | $170.1M | $827.1M | ||
| Q3 25 | $101.7M | $702.6M | ||
| Q2 25 | $150.2M | $364.0M | ||
| Q1 25 | $98.8M | $596.1M | ||
| Q4 24 | $190.4M | $742.5M | ||
| Q3 24 | $81.6M | $703.6M | ||
| Q2 24 | $146.0M | $658.2M | ||
| Q1 24 | $21.1M | $664.6M |
自由现金流ALKSRPRX
| Q4 25 | $170.0M | — | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | — | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSRPRX
| Q4 25 | 44.2% | — | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSRPRX
| Q4 25 | 0.0% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
现金转化率ALKSRPRX
| Q4 25 | 3.45× | 3.86× | ||
| Q3 25 | 1.23× | 2.44× | ||
| Q2 25 | 1.72× | 12.06× | ||
| Q1 25 | 4.40× | 2.50× | ||
| Q4 24 | 1.30× | 3.57× | ||
| Q3 24 | 0.88× | 1.29× | ||
| Q2 24 | 1.60× | 6.45× | ||
| Q1 24 | 0.57× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
